Neuroleptic malignant syndrome responsive to carbidopa/levodopa: support for a dopaminergic pathogenesis

Clin Neuropharmacol. 1987 Apr;10(2):186-9. doi: 10.1097/00002826-198704000-00010.

Abstract

A 31-year-old man with psychosis and neuroleptic-induced tardive dystonia developed neuroleptic malignant syndrome (NMS) while taking haloperidol. Muscle rigidity responded to dantrolene, but hyperthermia did not abate until therapy with carbidopa/levodopa was initiated, after which temperature varied in direct relationship to subsequent levodopa administration. This supports the role for central dopaminergic mechanisms in the pathogenesis of NMS.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Carbidopa / therapeutic use*
  • Drug Combinations
  • Haloperidol / adverse effects
  • Humans
  • Levodopa / therapeutic use*
  • Male
  • Neuroleptic Malignant Syndrome / drug therapy*
  • Psychotic Disorders / drug therapy

Substances

  • Drug Combinations
  • Levodopa
  • Haloperidol
  • Carbidopa